恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响*

doi:10.3969/j.issn.1672-5069.2018.06.010

实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (6): 863-867.doi: 10.3969/j.issn.1672-5069.2018.06.010

恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响^*

黄娇凤, 林苏, 王明芳, 黄映芳, 熊美连, 朱月永

350002 福州市福建医科大学附属第一医院肝病中心（黄娇凤,林苏,王明芳,朱月永）; 干部病房（黄映芳）; 影像科（熊美连）

收稿日期:2017-10-31 出版日期:2018-11-10 发布日期:2018-12-25
通讯作者: 朱月永,E-mail: zhuyueyong@fjmu.edu.cn
作者简介:黄娇凤,女,29岁,硕士研究生,住院医师。主要从事慢性乙型肝炎与脂肪肝诊治研究。E-mail:huangjiaofeng@fjmu.edu.cn
基金资助:
*福建省教育厅中青年教师教育科研基金资助项目（编号：JA15207 /JB12111）

Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease

Huang Jiaofeng, Lin Su, Wang Mingfang, et al.

Centre of Liver Disease Study,First Affiliated Hospital,Fujian Medical University,Fuzhou 350005,China

Received:2017-10-31 Online:2018-11-10 Published:2018-12-25
Contact: Corresponding author:Zhu Yueyong,E-mail:zhuyueyong@fjmu.edu.cn

摘要/Abstract

摘要： 目的探讨恩替卡韦治疗慢性乙型肝炎（CHB）合并非酒精性脂肪性肝病（NAFLD）患者疗效及其对脂肪肝的影响。方法 25例CHB患者接受恩替卡韦治疗96 w。经肝穿组织学检查行脂肪变分级,使用磁共振氢质子波谱成像（¹H -MRS）检测脂水比（LWR）以判断肝脂肪变变化。采用自行设计的健康问卷调查表调查生活习惯并予以量化。结果 25例CHB患者经组织病理学检查,发现脂肪变≥F1者16例（64.0%）,被认为合并脂肪肝;治疗96 w末,21例（84.0%）患者达到完全病毒学应答;治疗前后血清HBsAg和HBV DNA水平差异有统计学意义（P<0.05）,而血清TBIL、ALT、体质指数、腰臀比、低密度脂蛋白胆固醇等无统计学意义的变化（P>0.05）;根据治疗前后LWR变化,发现治疗后脂肪变变重者8例,未变者13例,改善者4例,而脂肪肝改善患者治疗后腰臀比显著下降（P<0.05）;对生活习惯得分分析发现,每日主食量对脂肪肝的影响比较大（P<0.05）,即每日主食量大者会加重脂肪肝。结论恩替卡韦治疗未能改善CHB合并NAFLD患者肝脏脂肪变程度,而这些患者在抗病毒的同时控制主食,降低腰臀比或许能减轻肝脂肪变程度。

关键词: 慢性乙型肝炎, 非酒精性脂肪肝, 恩替卡韦, 磁共振波谱, 疗效

Abstract: Objective To investigate the impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B （CHB） and nonalcoholic fatty liver disease （NAFLD）. Methods A total of 25 patients with histological-proved chronic hepatitis B（CHB） were enrolled in this prospective study. The patients were treated with entecavir for 96 weeks. The hydrogen proton spectroscopy（¹H-MRS） was performed and the life style was investigated by a questionnaire in all patients. Results 16 patients（64.0%） with CHB were found having liver steatosis≥F1 by liver biopsies. 21 patients （84.0%） obtained complete viralogic response at the end of 96 weeks;serum HBsAg and HBV DNA levels at baseline and at the end of observation were significantly different（P<0.05）,while there were no significant differences as respect to serum bilirubin,ALT,body mass index,waist-hip ratio and low-density lipoprotein cholesterol （P>0.05）;at the end of 96 weeks,8 were found having liver steatosis deteriorated,13 unchanged and 4 improved by the lipid-water ratio（LWR） of ¹H-MRS out of 16 patients with NAFLD and the waist-hip ratio decreased in those with improved steatosis（P<0.05）;the analysis of life habit showed that the staple food was the independent factor which influenced the outcome of hepatic steatosis （P<0.05）. Conclusion Entecavir treatment could not improve hepatic steatosis in patients with CHB and NAFLD,and the decreased waist-to-hip ratio might be associated the improvement of liver steatosis in those patients.

Key words: Hepatitis B, Nonalcoholic fatty liver disease, Entecavir, Magnetic resonance spectroscopy, Therapy

黄娇凤, 林苏, 王明芳, 黄映芳, 熊美连, 朱月永. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响^*[J]. 实用肝脏病杂志, 2018, 21(6): 863-867.

Huang Jiaofeng, Lin Su, Wang Mingfang, et al.. Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 863-867.

参考文献

[1] Peng D,Han Y,Ding H,et al.Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol,2008,23(7 Pt 1):1082-1088.
[2] 王明芳,林苏,吴银莲, 等. 慢性乙型肝炎患者肝脂肪变性与血清、肝组织病毒因素的关系. 中华传染病杂志,2016,34(3): 141-145.
[3] Kim K,Kim KH,Kim HH,et al.Hepatitis B virus X protein induces lipogenic transcriptio nfactor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem J,2008,416(2):219-230.
[4] Joo EJ,Chang Y,Yeom JS,et al.Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease:A cohort study. Hepatology,2017,65(3):828-835.
[5] Hamilton G,Yokoo T,Bydder M, et al.In vivo characterization of the liver fat H MR spectrum. NMR Biomed,2011,24(7):784-790.
[6] Stern C,Castera L.Non-invasive diagnosis of hepatic steatosis. Hepatol Int,2017,11(1):70-78.
[7] AlShaalan R,Aljiffry M,Al-Busafi S,et al. Nonalcoholic fatty liver disease:Noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol,2015,21(2):64-70.
[8] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89.
[9] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志,2007,10(1):1-3.
[10] Xiao G,Zhu S,Xiao X,et al.Comparison of laboratory tests,ultrasound,or MRE to detect fibrosis in patients with non-alcoholic fatty liver disease:A meta-analysis. Hepatology,2017,52:1-45.
[11] Di Martino M,Pacifico L,Bezzi M,et al.Comparison of magnetic resonance spectroscopy,proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents. World J Gastroenterol,2016,22(39):8812-8819.
[12] Chan R,Wong VW,Chu WC,et al.Diet-quality scores and prevalence of nonalcoholic fatty liver disease:A population study using proton-magnetic resonance spectroscopy. PLoS One,2015,10(9): 0139310.
[13] 曹代荣,熊美连,邢振,等. 磁共振、CT定量分析肝脏脂肪变准确性的对比研究. 临床放射学杂志,2012,31(11):1578-1582.
[14] Machado MV,Oliveira AG,Cortez-Pinto H,et al.Hepatic steatosis in hepatitis B virus infected patients:meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol,2011,26(9):1361-1367.
[15] Jarcuska P,Drazilova S,Fedacko J,et al.Association between hepatitis B and metabolic syndrome:Current state of the art. World J Gastroenterol,2016,22(1):155-164.
[16] Wah-Kheong C,Khean-Lee G.Epidemiology of a fast emerging disease in the Asia-Pacific region:non-alcoholic fatty liver disease. Hepatol Int,2013,7(1):65-71.
[17] Jin X,Chen YP,Yang YD,et al.Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One,2012,7(3):e34198.
[18] Gong L,Liu J,Wang J,et al.Hepatic steatosis as a predictive factor of antiviral effect of pegylated interferon therapy in patients with hepatitis B. Transplant Proc,2015,47(10):2886-2891.
[19] Cindoruk M,Karakan T,Unal S,et al.Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol,2007,41(5):513-517.
[20] Zhu LY,Wang YG,Wei LQ,et al.The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease. Drug Des Devel Ther,2016,10:2739-2744.
[21] 蒋瓅,陈雪婉,郑瑞丹,等. 腰臀比为非酒精性单纯性脂肪肝最有效的预测指标. 中华肝脏病杂志,2010,18(11):859-861.

恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响^*

Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[6]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[7]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[8]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	巴正武, 栗海龙, 杨慧. 能谱CT成像定量评估Budd-Chiari综合征患者TIPS术治疗前后肝功能状态临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(5): 680-683.
[11]	张志成, 袁广庆, 莫灿均. 肝动脉栓塞术治疗三种类型肝血管瘤患者疗效及安全性分析*[J]. 实用肝脏病杂志, 2019, 22(5): 736-739.
[12]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[13]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[14]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[15]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.